Año 2022 / Volumen 114 / Número 1
Original
Irritable bowel syndrome and basal serum tryptase: correlation between subtype, severity, and comorbidities. A pilot study

22-27

DOI: 10.17235/reed.2021.7697/2020

Constanza Ciriza de los Ríos, Isabel Castel de Lucas, Fernando Canga Rodríguez-Valcárcel, María del Carmen Diéguez Pastor, Natividad de las Cuevas Moreno, Enrique Rey Díaz-Rubio,

Resumen
Introduction: the activation of mast cells causes alterations in epithelial and neuromuscular function and is involved in visceral hypersensitivity and dysmotility in gastrointestinal functional disorders. Objectives: primary: to evaluate differences in basal serum tryptase (BST) between patients with irritable bowel syndrome (IBS) and healthy controls. Secondary: BST depending on IBS subtype (diarrhea: IBS-D; constipation: IBS-C), comorbidities and correlation with IBS severity and quality of life. Material and methods: a prospective control-case study in IBS patients (Rome IV criteria). BST (ImmunoCAP-Phadia, Sweden®), IBS Severity Score (IBSSS), pain, bloating and flatulence analogue scales, IBS quality of life (IBSQOL), and patient health status (PHQ-9) were determined. BST is the primary variable to achieve the primary endpoint. Results: thirty-two patients were included, 21 (65.6 %) with IBS-D and 11 (34.4 %) with IBS-C; 32 controls were also included. Mean IBSSSS: 326.6 (± 71.4), IBSQOL: 76 (± 20.3), and PHQ9: 10.2 (± 5.9). BST was 4.8 ± 2.6 in IBS and 4.7 ± 2.6 in controls (p = 0.875). There were no differences in BST between IBS subtypes (4.7 ± 2.9 in IBS-D and 5 ± 1.8 in IBS-C; p = 0.315) or IBS severity (p = 0.662). However, BST was higher in patients with IBS and extraintestinal comorbidities compared to other patients and controls (p = 0.029). This subgroup also has more severe bloating (p = 0.021). There was no correlation between BST, quality of life (p = 0.9260), and health status (p = 0.3985). Conclusion: BST does not discriminate between IBS patients and controls. However, BST was higher in patients with IBS with extraintestinal comorbidities, which had more severe bloating. This finding is worthy of investigation.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Rizzi A, Crivellato E, Benagiano V, et al. Mast cells in human digestive tube in normal and pathological conditions. Immunol Lett 2016;177:16-21. DOI: 10.1016/j.imlet.2016.07.002
2. Bischoff SC. Physiological and pathophysiological functions of intestinal mast cells. Semin Immunopathol 2009;31(2):185-205. DOI: 10.1007/s00281-009-0165-4
3. Bachelet I, Levi-Schaffer F, Mekori YA. Mast cells: not only in allergy. Immunol Allergy Clin North Am 2006;26(3):407-25. DOI: 10.1016/j.iac.2006.05.007
4. Wouters MM, Vicario M, Santos J. The role of mast cells in functional GI disorders. Gut 2016;65(1):155-68. DOI: 10.1136/gutjnl-2015-309151
5. Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation or should it be mast cell mediator disorders? Expert Rev Clin Immunol 2019;15(6):639-56. DOI: 10.1080/1744666X.2019.1596800
6. Valent P, Sperr WR, Sotlar K, et al. The serum tryptase test: an emerging robust biomarker in clinical hematology. Expert review of hematology 2014;7(5):683-90. DOI: 10.1586/17474086.2014.955008
7. Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 2016;48(12):1564-9. DOI: 10.1038/ng.3696
8. Bischoff SC. Mast cells in gastrointestinal disorders. Eur J Pharmacol 2016;778:139-45. DOI: 10.1016/j.ejphar.2016.02.018
9. Gaudenzio N, Sibilano R, Starkl P, et al. Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice. J Vis Exp 2015;(99):e52753. DOI: 10.3791/52753
10. Reber LL, Sibilano R, Mukai K, et al. Potential effector and immunoregulatory functions of mast cells in mucosal immunity. Mucosal Immunol 2015;8(3):444-63. DOI: 10.1038/mi.2014.131
11. Palsson OS, Whitehead W, van Tilburg MA, et al. Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. Gastroenterology 2016;S0016-5085(16)00180-3. DOI: 10.1053/j.gastro.2016.02.014
12. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47(6):804-11. DOI: 10.1136/gut.47.6.804
13. Grover M. Role of gut pathogens in development of irritable bowel syndrome. Indian J Med Res 2014;139(1):11-8.
14. Barbara G, Stanghellini V, De Giorgio R, et al. Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil 2006;18(1):6-17. DOI: 10.1111/j.1365-2982.2005.00685.x
15. Barbara G, Stanghellini V, DeGiorgio R, et al. Activated mast cells in proximity to colonic nerves correlates with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126(3):693-702. DOI: 10.1053/j.gastro.2003.11.055
16. Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil 2017;23(2):151-63. DOI: 10.5056/jnm16214
17. Almansa C, García-Sánchez R, Barceló M, et al. Translation, cultural adaptation and validation of a Spanish version of the Irritable Bowel Syndrome Severity Score. Rev Esp Enferm Dig 2011;103(12):612-8. DOI: 10.4321/s1130-01082011001200002
18. Badia X, Herdman M, Mearin F, et al. Adaptación al español del cuestionario IBSQoL para la medición de la calidad de vida en pacientes con síndrome de intestino irritable. Rev Esp Enferm Dig 2000;92:637-43.
19. Diez-Quevedo C, Rangil T, Sanchez-Planell L, et al. Validation and utility of the patient health questionnaire in diagnosing mental disorders in 1003 general hospital Spanish inpatients. Psychosom Med 2001;63(4):679-86. DOI: 10.1097/00006842-200107000-00021
20. Schwartz LB, Bradford TR, Rouse C, et al. Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol 1994;14(3):190-204. DOI: 10.1007/bf01533368
21. Jones I, Peterson CGB. Normal day to day variations of tryptase in serum. Allergy 2000;55(suppl 63):214-5.
22. Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007;56(2):203-9. DOI: 10.1136/gut.2006.100594
23. Martin-Viñas JJ, Quigley EM. Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators. J Dig Dis 2016;17(9):572-81. DOI: 10.1111/1751-2980.12379
24. Burns G, Carroll G, Mathe A, et al. Evidence for Local and Systemic Immune Activation in Functional Dyspepsia and the Irritable Bowel Syndrome: A Systematic Review. Am J Gastroenterol 2019;114(3):429-36. DOI: 10.1038/s41395-018-0377-0
25. Zhang L, Song J, Hou X. Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside. J Neurogastroenterol Motil 2016;22(2):181-92. DOI: 10.5056/jnm15137
26. Fellinger C, Hemmer W, Wöhrl S, et al. Clinical characteristics and risk profile of patients with elevated baseline serum tryptase. Allergol Immunopathol (Madr) 2014;42(6):544-52. DOI: 10.1016/j.aller.2014.05.002
27. Liang WJ, Zhang G, Luo HS, et al. Tryptase and Protease-Activated Receptor 2 Expression Levels in Irritable Bowel Syndrome. Gut Liver 2016;10(3):382-90. DOI: 10.5009/gnl14319
28. Petersen MW, Schröder A, Jørgensen T, et al. Irritable bowel, chronic widespread pain, chronic fatigue and related syndromes are prevalent and highly overlapping in the general population: DanFunD. Sci Rep 2020;10(1):2373. DOI: 10.1038/s41598-020-60318-6
29. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 2004;146(1-2):1-12. DOI: 10.1016/j.jneuroim.2003.10.041
30. de Rossi TM, Krauss N, Wilken V, et al. Mast cell tryptase in sera of patients with Crohn's disease and mastocytosis. Eur J Gastroenterol Hepatol 2009;21(3):273-7. DOI: 10.1097/MEG.0b013e3283218392
Artículos relacionados
Instrucciones para citar
Ciriza de los Ríos C, Castel de Lucas I, Canga Rodríguez-Valcárcel F, Diéguez Pastor M, de las Cuevas Moreno N, Rey Díaz-Rubio E, et all. Irritable bowel syndrome and basal serum tryptase: correlation between subtype, severity, and comorbidities. A pilot study. 7697/2020


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 719 veces.
Este artículo ha sido descargado 140 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 01/12/2020

Aceptado: 27/01/2021

Prepublicado: 10/02/2021

Publicado: 10/01/2022

Tiempo de revisión del artículo: 54 días

Tiempo de prepublicación: 71 días

Tiempo de edición del artículo: 405 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas